GSK moved to shut down camlipixant after mixed Phase 3 results in refractory chronic cough (RCC). The company said the pill is unlikely to transform patient care, and it will discontinue the program across the indication. The readthrough follows contradictory outcomes across the CALM-1 and CALM-2 trials and highlights continued difficulty for P2X3 antagonists in delivering consistent efficacy. Trevi Therapeutics’ alternative approach in chronic cough was positioned as a beneficiary as GSK’s development activity ends.